TNFRSF17 and Miyoshi myopathy: AMG420, a BiTE against B cell maturation antigen (BCMA) and CD3, completed a dose escalation, multi-centered phase I trial in 2019 where MM was treated by proximity-based T cell-mediated lysis of BCMA-positive cells such as MM cells and plasma cells.